|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,413,525: Infigratinib (Truseltiq)
Patent 10,413,525, granted September 17, 2019, to QED Therapeutics, Inc., covers the compound infigratinib, a small molecule inhibitor of fibroblast growth factor receptor (FGFR) kinases. Infigratinib is approved by the U.S. Food and Drug Administration (FDA) as Truseltiq for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or other rearrangement. This analysis details the patent's scope, claims, and the broader patent landscape surrounding infigratinib.
What Does Patent 10,413,525 Claim?
Patent 10,413,525 claims the compound infigratinib and its use in treating FGFR-driven cancers. The patent's validity and enforceability are central to the commercial exclusivity of Truseltiq.
What is the Core Chemical Structure Claimed?
The primary claim of the patent is for the specific chemical compound.
- Claim 1: "A compound of Formula I or a pharmaceutically acceptable salt thereof:"
- Formula I is depicted in the patent and represents infigratinib with the chemical name N-(5-(3-chloro-1H-indazol-6-yl)-2,4-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-2-(4-morpholinyl)acetamide.
- This claim encompasses the free base and any pharmaceutically acceptable salt forms of the compound, broadening the patent's reach to various formulations that incorporate the active pharmaceutical ingredient.
What Therapeutic Uses Are Covered?
The patent asserts claims for the treatment of specific medical conditions, particularly those driven by aberrant FGFR signaling.
- Claim 11: "A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof."
- This claim broadly covers the use of infigratinib for treating any cancer.
- Claim 12: "The method of claim 11, wherein the cancer is a cholangiocarcinoma."
- This claim narrows the therapeutic application to cholangiocarcinoma, the indication for which Truseltiq is approved.
- Claim 13: "The method of claim 12, wherein the cholangiocarcinoma has an FGFR2 fusion or rearrangement."
- This claim further refines the therapeutic target, specifying the genetic alterations that make a cholangiocarcinoma susceptible to infigratinib treatment. This precision aligns with the drug's mechanism of action and the patient population identified for its efficacy.
What Are the Key Exclusivity Provisions?
The patent grants exclusive rights to the patent holder for the claimed invention in the United States.
- Term: United States patents are typically granted for a term of 20 years from the filing date, subject to maintenance fees. Patent 10,413,525 was filed on January 27, 2017, and granted on September 17, 2019. Its expiration date is projected to be January 27, 2037, barring any extensions.
- Enforcement: The patent holder has the right to exclude others from making, using, selling, offering for sale, or importing the patented compound and methods of use in the United States during the patent term. Infringement can lead to legal action and damages.
What is the Patent Landscape for Infigratinib?
The patent landscape for infigratinib is complex, involving not only the compound itself but also its synthesis, formulations, and methods of use. Multiple patents protect various aspects of the drug's development and commercialization.
Key Patents Protecting Infigratinib
Beyond the core compound patent, other patents contribute to the intellectual property surrounding infigratinib.
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Key Focus |
| US 10,413,525 B2 |
INDAZOLE DERIVATIVES AS KINASE INHIBITORS |
QED Therapeutics, Inc. |
Jan 27, 2017 |
Sep 17, 2019 |
The infigratinib compound (Formula I) and its use in treating cancer, specifically cholangiocarcinoma with FGFR2 alterations. |
| US 9,873,637 B2 |
PYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS |
QED Therapeutics, Inc. |
May 23, 2014 |
Jan 23, 2018 |
A broader class of pyrazolo[3,4-d]pyrimidine compounds, including infigratinib, as kinase inhibitors. This patent may cover earlier iterations or related compounds. |
| US 9,260,400 B2 |
MODULATORS OF FGFR AND USES THEREOF |
QED Therapeutics, Inc. |
Mar 24, 2015 |
Feb 16, 2016 |
Focuses on modulators of FGFR activity and their therapeutic uses, potentially covering infigratinib and its mechanism of action. |
| US 11,090,584 B2 |
COMPOUNDS AND METHODS FOR TREATING CANCER |
QED Therapeutics, Inc. |
Mar 11, 2020 |
Aug 17, 2021 |
Covers specific pharmaceutical compositions and methods for treating cancers, likely including formulations or improved delivery methods for infigratinib. |
| US 11,534,537 B2 |
COMPOUNDS AND METHODS FOR TREATING CANCER |
QED Therapeutics, Inc. |
Oct 27, 2021 |
Dec 27, 2022 |
Continues to protect methods of treating cancer, potentially addressing new indications or improved treatment regimens involving infigratinib. |
Source: United States Patent and Trademark Office (USPTO) database searches.
Analysis of Overlapping and Complementary Patents
The patent portfolio for infigratinib demonstrates a strategy of building layered protection.
- Core Compound: US 10,413,525 is the primary patent for the infigratinib molecule itself.
- Broader Chemical Scaffolds: US 9,873,637 and US 9,260,400 represent earlier, broader claims to chemical classes that encompass infigratinib or its functional mechanisms. These may provide a fallback if the core compound patent faces challenges.
- Method of Use and Formulation: Patents like US 11,090,584 and US 11,534,537 indicate ongoing innovation in how infigratinib is formulated, administered, or applied to new therapeutic scenarios. These can extend market exclusivity beyond the expiry of the primary compound patent.
Patent Challenges and Litigation
The strength of the patent landscape can be tested through legal challenges.
- Inter Partes Review (IPR): Competitors may file IPRs with the USPTO to challenge the validity of patents based on prior art. Such challenges can lead to patent claims being invalidated or narrowed.
- Infringement Litigation: If a generic manufacturer seeks to launch an infigratinib product, the patent holder would likely initiate infringement lawsuits based on its active patents. These cases often involve extensive discovery and expert testimony regarding patent scope and infringement.
What is the Regulatory Status and Market Exclusivity?
The FDA approval of Truseltiq is intertwined with patent protection, creating a period of market exclusivity.
FDA Approval and Orphan Drug Designation
- FDA Approval Date: Truseltiq (infigratinib) received accelerated approval from the FDA on May 28, 2021. [1]
- Orphan Drug Designation: Infigratinib was granted Orphan Drug Designation by the FDA for the treatment of cholangiocarcinoma. This designation provides incentives such as market exclusivity for a period of seven years following approval for a rare disease. [2]
- Accelerated Approval: The accelerated approval pathway allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on a surrogate endpoint or intermediate clinical outcome. Post-marketing confirmatory trials are required to verify the clinical benefit.
Market Exclusivity Periods
Market exclusivity refers to the period during which generic versions of a drug cannot be marketed. This exclusivity can stem from several sources:
- Patent Exclusivity: As detailed by US 10,413,525, this exclusivity is tied to the life of the patent, projected to January 27, 2037.
- Orphan Drug Exclusivity (ODE): The seven-year ODE provides protection independent of patent status. For Truseltiq, this would extend to May 28, 2028. [2]
- New Chemical Entity (NCE) Exclusivity: While infigratinib is approved as an NCE, this exclusivity is typically granted by the FDA for five years from the date of approval, allowing the patent holder to realize market benefits.
The interplay of these exclusivity periods creates a complex, layered protection for Truseltiq. The most significant period of market exclusivity is currently dictated by the life of the core compound patent (US 10,413,525).
What Are the Key Takeaways?
Patent 10,413,525 provides core patent protection for the infigratinib compound, infigratinib, and its use in treating FGFR2-driven cholangiocarcinoma. This patent, along with a portfolio of related patents covering broader chemical scaffolds and methods of use, establishes a robust intellectual property framework for QED Therapeutics, Inc. The patent's projected expiration in January 2037 provides a significant period of market exclusivity, further reinforced by Orphan Drug Exclusivity extending to May 2028. This combined exclusivity shields Truseltiq from generic competition for an extended duration, supporting R&D investment recovery and market positioning for the treatment of this specific cancer indication.
FAQs
1. What is the primary legal protection afforded by US Patent 10,413,525?
The patent claims the specific chemical compound infigratinib and its use in treating cancer, particularly cholangiocarcinoma with FGFR2 alterations. This grants the patent holder exclusive rights to make, use, sell, offer for sale, or import the compound for these purposes within the United States.
2. How long is the projected period of exclusivity for infigratinib based on this patent?
Based on a filing date of January 27, 2017, and a grant date of September 17, 2019, the patent is projected to expire on January 27, 2037, assuming all maintenance fees are paid.
3. Does this patent prevent the development of similar FGFR inhibitors?
This patent specifically claims infigratinib and its use. It does not prevent competitors from developing and patenting different FGFR inhibitors with distinct chemical structures or novel mechanisms of action, provided they do not infringe on the claims of US 10,413,525 or other relevant patents.
4. What are the implications of the Orphan Drug Designation for infigratinib's market exclusivity?
Orphan Drug Designation provides seven years of market exclusivity from the date of approval (May 28, 2021) for the treatment of cholangiocarcinoma. This means that the FDA cannot approve a generic version of Truseltiq for the same indication during this period, irrespective of patent status.
5. Can competitors challenge the validity of Patent 10,413,525?
Yes, competitors can challenge the validity of the patent through mechanisms like Inter Partes Review (IPR) at the USPTO or in patent infringement litigation. Challenges typically focus on arguments that the claimed invention was not novel or was obvious in light of prior art existing before the patent's filing date.
Citations
[1] U.S. Food and Drug Administration. (2021, May 28). FDA approves first FGFR inhibitor for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-fgfr-inhibitor-previously-treated-unresectable-locally-advanced-or-metastatic
[2] QED Therapeutics, Inc. (n.d.). Truseltiq™ (infigratinib) Prescribing Information. (Provided as part of the drug approval process, specific document link may vary). Information on Orphan Drug Designation is typically found in FDA drug approval notices and company regulatory filings.
More… ↓
⤷ Start Trial
|
